Compare Fidelity National Information Servcs Inc (FIS) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Gilead Sciences, Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $41.54 (market cap $21.24B), while Gilead Sciences, Inc. trades at $133.66 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 7.7× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4.09%). Which is the better fit depends on your goals.
| FIS | GILD | |
|---|---|---|
Market Cap | $21.24B | $163.51B |
Sector | Technology | Health |
52-Week High | $81.94 | $155.80 |
52-Week Low | $37.72 | $108.22 |
Enterprise Value | $41.63B | $178.05B |
Dividend Yield | 4.09% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS (Fidelity National Information Services) trades at $40.58, down 3.22% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $1.36 versus $1.29, and analyst consensus remains strong with 21 Buy ratings and a $52.57 price target. Recent business developments include winning Frankfurt International Bank as a cloud banking client and receiving industry awards for AI-embedded risk technology.
The outlook presents a value opportunity with a low P/E of 7.97 and improving profit margins, though execution risks persist from the Worldpay divestiture and net cash flow volatility. Upside potential exists if the company capitalizes on its $42 billion market opportunity in digital payments and maintains its recent earnings momentum.
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
